AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00617669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral tablet once daily
Trial: NCT01460199
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT00649259
Drug: Ditropan XL® Tablets 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x10mg, single dose fed
Trial: NCT02875574
Drug: Any treatment regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
Trial: NCT02127268
Drug: Thymosin-α1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: with Thymosin-α1 1.6mg twice a week
Trial: NCT03218683
Drug: AZD5991
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses
Trial: NCT03960450
Drug: BOS-475
RxNorm normalized name: BOS TAURUS EYE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cream
Trial: NCT03960450
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cream
Trial: NCT03790423
Drug: Injection of 18F-ASIS
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)
Trial: NCT02373072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects completing all three treatment periods will be receiving placebo once.
Trial: NCT01313273
Drug: Non steroidal anti androgens and LHRH-a
RxNorm normalized name: Anti-androgens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
Trial: NCT00134784
Drug: [123I]B-CIT SPECT imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess \[123I\]B-CIT SPECT imaging
Trial: NCT02732197
Drug: Sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
Trial: NCT02732197
Drug: No sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parturients did not receive any type of sedation after spinal anesthesia.
Trial: NCT00762424
Drug: Flowmax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg once a day until stone passage total = 9 tablets
Trial: NCT00762424
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cornstarch
Trial: NCT01347580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by oral Ticagrelor loading dose (180 mg)
Trial: NCT02605044
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02397499
Drug: LIPO-202
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02397499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03416062
Drug: Remaxol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
Trial: NCT03550859
Drug: Telmisartan/Rosuvastatin 40/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
Trial: NCT02885259
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human immunoglobulin and one vial of recombinant human hyaluronidase
Trial: NCT02587000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01270659
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet 100 mcg once
Trial: NCT01270659
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet 200 mcg once
Trial: NCT03860935
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active control administered orally twice daily (BID)
Trial: NCT01485588
Drug: hI-con1™ 300µl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
Trial: NCT00266851
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg x 3 days, then 600 mg weekly x 11 weeks
Trial: NCT00266851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01661088
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1.
Trial: NCT00246571
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
Trial: NCT00246571
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~1. Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~2. Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~3. Docetaxel - 75-100 mg/m2 every 3 weeks~4. Paclitaxel - 175-200 mg/m2 every 3 weeks~5. Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~6. Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248.
Trial: NCT01012648
Drug: HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume Resuscitation
Trial: NCT02331095
Drug: Anticoagulation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
Trial: NCT02552394
Drug: huJ591
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
Trial: NCT04469829
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 15 mg/week
Trial: NCT03163602
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access flap and debridement
Trial: NCT02024152
Drug: JDP-205 IM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02024152
Drug: Control: Zyrtec
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04454619
Drug: Hand antisepsis with Clorhexidine and solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
Trial: NCT00000477
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04549207
Drug: Bone modifying agent
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of bone modifying agent
Trial: NCT00744354
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, 30mg/m2, Day 4, each cycle
Trial: NCT04040907
Drug: XNW3009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XNW3009 is a small molecule hURAT1 inhibitor
Trial: NCT04040907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and active drug will have the same appearance
Trial: NCT00799773
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
Trial: NCT02513693
Drug: Standard neuromuscular blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
Trial: NCT02513693
Drug: Deep neuromuscular blockade
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
Trial: NCT03758885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single oral administration
Trial: NCT02359175
Drug: Fentanyl in epidural catheter
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl to be given in epidural catheter
Trial: NCT02736409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo dose
Trial: NCT02359175
Drug: Oral Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol to be given orally
Trial: NCT02359175
Drug: Oral NSAID
RxNorm normalized name: Ansaid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID to be given orally
Trial: NCT02359175
Drug: Oral opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids to be given orally
Trial: NCT02359175
Drug: Placebo (for oral opioids)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to be given instead of oral opioids
Trial: NCT03771898
Drug: SHP611
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.
Trial: NCT04528355
Drug: data collection
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
Trial: NCT03492840
Drug: RZL-012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites
Trial: NCT03253471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Match AL-611
Trial: NCT01221844
Drug: FerroGrad by Abbott
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
Trial: NCT00416897
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00282464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
Trial: NCT03748043
Drug: Ferric Hydroxide Polymaltose
RxNorm normalized name: ferric hydroxide
DrugBank: Ferric hydroxide (DB13423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
Trial: NCT02202356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02554279
Drug: recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01348009
Drug: Tesetaxel-capecitabine-cisplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.
Trial: NCT00291356
Drug: GSK189075 oral tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00291356
Drug: GW869682 oral tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02239120
Drug: optional ASA as comedication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
Trial: NCT02239120
Drug: placebo to ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to comparator drug
Trial: NCT02239120
Drug: placebo to optional ASA as comedication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
Trial: NCT01976988
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
Trial: NCT02414568
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 40 mg/m² IV
Trial: NCT00500656
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard capsule matched to tranexamic acid
Trial: NCT00500656
Drug: S.C. Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection, matched to icatibant for injection
Trial: NCT01119937
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
Trial: NCT03446144
Drug: Placebo (sterline saline 0.9%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
Trial: NCT02224118
Drug: CNTO 3649 10 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
Trial: NCT02224118
Drug: CNT0 3649 30 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
Trial: NCT02224118
Drug: CNTO 3649 100 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
Trial: NCT02224118
Drug: CNTO 3649 300 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
Trial: NCT02224118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
Trial: NCT01986777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsules will be filled with lactose.
Trial: NCT03485495
Drug: Divaza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT03485495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT01323920
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 15 mg/m\^2 IV
Trial: NCT00081510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02025621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04559529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
Trial: NCT00689273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
Trial: NCT00098982
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00098982
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00518960
Drug: ProAlgaZyme
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00881543
Drug: Dipeptidyl Peptidase IV inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage 100 mg each day, once a day, 2 months
Trial: NCT00484185
Drug: BeneFIX (coagulation factor IX (recombinant))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BeneFIX will be administered according to physician's discretion.
Trial: NCT00494767
Drug: GW869682
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW869682 tablet with a dose strength of 250 mg will be available for subjects
Trial: NCT00494767
Drug: GSK189075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK189075 tablet with a dose strength of 250 mg will be available for subjects
Trial: NCT00494767
Drug: GSK189075-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match GSK189075 250 mg will be available for subjects
Trial: NCT00494767
Drug: GW869682-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match GW869682 250 mg will be available for subjects
Trial: NCT03956368
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg (every evening orally) for 8 weeks.
Trial: NCT01478360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous injection
Trial: NCT00619905
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01909752
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
Trial: NCT03836807
Drug: OKITASK®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of OKITASK® 40 mg was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained KLS 40 mg (equivalent to 25 mg of ketoprofen). The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
Trial: NCT02679339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01101191
Drug: Reformulated OXY (oxycodone HCl)
RxNorm normalized name: Oxy Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated OXY 80-mg tablet x 1 dose taken without food.
Trial: NCT01101191
Drug: Original OxyContin® (OXY) (oxycodone HCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
Trial: NCT01612052
Drug: Antibiotic Prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparing the antibiotic treatment related to surgery
Trial: NCT00123890
Drug: GW873140
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02038569
Drug: LEO 80185 gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no